# 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN

> **NCT01822652** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Baylor College of Medicine** · enrollment: 11 (actual)

## Conditions studied

- Neuroblastoma

## Interventions

- **GENETIC:** iC9-GD2 T Cells - frozen
- **GENETIC:** iC9-GD2 T Cells - fresh
- **DRUG:** Cytoxan
- **DRUG:** Fludara
- **DRUG:** Keytruda
- **GENETIC:** iC9-GD2 T cells

## Key facts

- **NCT ID:** NCT01822652
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2013-08
- **Primary completion:** 2015-12
- **Final completion:** 2030-10
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01822652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01822652, "3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01822652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*